Cantor Fitzgerald Reiterates Overweight on Denali Therapeutics, Maintains $85 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Denali Therapeutics (NASDAQ:DNLI) and maintained an $85 price target.
June 22, 2023 | 1:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Denali Therapeutics and maintained an $85 price target.
The reiteration of an Overweight rating and maintenance of an $85 price target by Cantor Fitzgerald analyst Charles Duncan indicates a positive outlook for Denali Therapeutics. This news is likely to have a positive impact on DNLI's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100